DC Chemicals · Product datasheet

Atosiban — Datasheet

CAT. NO. DC23939

Product page and current package options

ParameterValue
Chemical NameAtosiban
CAS No.90779-69-4
SynonymsAtosiban;1-deamino-2d-tyr-(oet)-4-thr-8-orn-oxytocin;oxytocin,1-(3-mercaptopropanoicacid)-2-(o-ethyl-d-tyrosine)-4-l-threonine-8-l;rwj22164;ATOSIBAN ACETATE;1-(3-Mercaptopropionic acid)-2-(3-(p-ethoxyphenyl)-D-alanine)-4-L-thre onine-8-L-ornithineoxytocin;[Mpr-D-Tyr(OEt)-Ile-Thr-Asn-Cys]-Pro-Orn-Gly-NH2;(2S)-N-[(1S)-4-Amino-1-(carbamoylmethylcarbamoyl)butyl]-1-[(4S,7S,13S,16R)-13-[(2S)-butan-2-yl]-7-(carbamoylmethyl)-16-[(4-ethoxyphenyl)methyl]-10-(1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide;1-(3-Mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithineoxytocin;(Deamino-Cys1,D-Tyr(Et)2,Thr4,Orn8)-Oxytocin;1-Deamino-2-D-Tyr-(O-ethyl)-4-Thr-8-ornoxytocin;RW22164;Tractocile;(2S)-N-[(1S)-4-Amino-1-(carbamoylmethylcarbamoyl)butyl]-1-[(4S;Antocin;Rwj 22164;dTVT;081D12SI0Z;Atosibanum [INN-Latin];deTVT;Atosibanum;ORF 22164;Antocin II;Atosiban [USAN:INN:BAN];1-(3-Mercaptopropionic acid)-2-(3-(p-ethoxyphenyl)-D-alanine)-4-L-threonine-8-L-ornithineoxytocin;C43H67N11O12S2;1-(3-Mercaptopropanoic acid)-2-(O-ethy;1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane, cyclic peptide deriv. (ZCI);Oxytocin, 1-(3-mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithine- (ZCI);Antocile;CAP 449;CAP 476;CAP 581;F 314;RW 22164;DTXSID90861122;CAS_90779-69-4;(2S)-N-[5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,16R)-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide;AKOS015895131;MFCD00672436;NCGC00387803-01;BCP02053;1-[7-(2-Amino-2-oxoethyl)-13-(butan-2-yl)-16-[(4-ethoxyphenyl)methyl]-10-(1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl]prolylornithylglycinamide;SY301205;BDBM86209;90779-69-4;CAP-476;CAP-476;CAP-476;CAP-476;CAP-476;ATOSIBAN (MART.);ATOSIBAN (MART.);ATOSIBAN (MART.);ATOSIBAN (MART.);ATOSIBAN (MART.);d(D-Tyr(Et)2,Thr4,Orn8)vasotocin;d(D-Tyr(Et)2,Thr4,Orn8)vasotocin;d(D-Tyr(Et)2,Thr4,Orn8)vasotocin;d(D-Tyr(Et)2,Thr4,Orn8)vasotocin;d(D-Tyr(Et)2,Thr4,Orn8)vasotocin;RW22164;RWJ22164;RW22164;RWJ22164;RW22164;RWJ22164;RW22164;RWJ22164;RW22164;RWJ22164;C77085;C77085;C77085;C77085;C77085;CAS-90779-69-4;CAS-90779-69-4;CAS-90779-69-4;CAS-90779-69-4;CAS-90779-69-4;Atosibanum (INN-Latin);Atosibanum (INN-Latin);Atosibanum (INN-Latin);Atosibanum (INN-Latin);Atosibanum (INN-Latin);(Deamino-Cys1,D-Tyr(Et)2,Thr4,Orn8)-Oxytocin acetate salt;(Deamino-Cys1,D-Tyr(Et)2,Thr4,Orn8)-Oxytocin acetate salt;(Deamino-Cys1,D-Tyr(Et)2,Thr4,Orn8)-Oxytocin acetate salt;(Deamino-Cys1,D-Tyr(Et)2,Thr4,Orn8)-Oxytocin acetate salt;(Deamino-Cys1,D-Tyr(Et)2,Thr4,Orn8)-Oxytocin acetate salt;DTXSID8048991;DTXSID8048991;DTXSID8048991;DTXSID8048991;DTXSID8048991;GTPL2213;...
FormulaC43H67N11O12S2
M.Wt994.188587427139
SMILESC([C@@H]1CSSCCC(=O)N[C@H](CC2C=CC(OCC)=CC=2)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC(=O)N)C(=O)N1)(N1CCC[C@H]1C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)=O
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

Atosiban(RW22164; Tractocile) is a nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist (VOTra). Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane.As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua.[1][2] In human pre-term labour, atosiban, at the recommended dosage, antagonises uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.

In Vitro

No in vitro data are provided in the current product source. Contact us for further information.

In Vivo

No in vivo data are provided in the current product source. Contact us for further information.

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Cart

Request quotation